<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04546828</url>
  </required_header>
  <id_info>
    <org_study_id>2020-05-007</org_study_id>
    <nct_id>NCT04546828</nct_id>
  </id_info>
  <brief_title>A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea</brief_title>
  <official_title>A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Phase of Development: II&#xD;
&#xD;
        2. Patient Population: Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma&#xD;
&#xD;
        3. Estimated Number of Patients: 34 patients&#xD;
&#xD;
        4. Primary Objective: To assess the resetability of neoadjuvant chemotherapy including&#xD;
           gemcitabine, cisplatin, and nab-paclitaxel for resectable oncologically high-risk&#xD;
           intrahepatic cholangiocarcinoma that is treated with surgical resection. Thus, the&#xD;
           primary aim is to increase R0 resection rate via completion of all treatment&#xD;
&#xD;
        5. Secondary Objectives:&#xD;
&#xD;
      1) To assess the radiological response rate according to Response Evaluation Criteria in&#xD;
      Solid Tumors (RECIST) 2) To determine the overall resection rate 3) To determine&#xD;
      recurrence-free survival (RFS) 4) To identify patients' overall survival (OS) rate. 5) Saftey&#xD;
      and tolerability 6.Exploratory Endpoint : QoL analysis via EORTC QLO C-30&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-institution, open label phase II study designed to investigate the&#xD;
      feasibility of gemcitabine/cisplatin/nab-paclitaxel as a neoadjuvant systemic chemotherapy&#xD;
      for patients with reseactable oncologically high-risk IHCCA. This study will enroll up to 34&#xD;
      patients from all participating institutions with an accrual rate of 2 patients per month.&#xD;
&#xD;
      This will be an open-label, single arm study with each cycle equal to 21 days. All three&#xD;
      drugs will be administered intravenously on day 1 and day 8 of each cycle. Dosing will be&#xD;
      calculated using body surface area (BSA) based on the actual weight of the patient at each&#xD;
      visit. Nab-Paclitaxel will be given at 100 mg/m2, followed by cisplatin at 25 mg/m2 and then&#xD;
      gemcitabine at 800 mg/m2 for 2 weeks in a row followed by a week of rest. Patients will&#xD;
      receive 4 cycles of neoadjuvant systemic chemotherapy. Restaging will be done after every 2&#xD;
      cycles (+/- 1 week) by radiological imaging. If radiological scans demonstrate stable disease&#xD;
      or partial or complete tumor response and the tumor remains resectable, surgery will be&#xD;
      performed. For patients with radiological scans that document disease progression during the&#xD;
      study, treatment will be discontinued off the protocol and will not be evaluable for other&#xD;
      secondary endpoints. Resection will be performed per standard of care and will include a&#xD;
      portal lymphadenectomy for all cases. Objective evidence of recurrent disease after resection&#xD;
      will be recorded at the time of recurrence. Patients will be followed for overall survival&#xD;
      endpoint as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased rate of RO resection</measure>
    <time_frame>16weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the radiological response rate</measure>
    <time_frame>8weeks</time_frame>
    <description>To assess the radiological response rate according to Response Evaluation Criteria in Solid Tumors</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine, Cisplatin, and Nab-Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:&#xD;
Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:&#xD;
Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Cisplatin, and Nab-Paclitaxe</intervention_name>
    <description>Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:&#xD;
Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:&#xD;
Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days .</description>
    <arm_group_label>Gemcitabine, Cisplatin, and Nab-Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of intrahepatic cholangiocarcinoma&#xD;
&#xD;
          2. Oncologic high-risk disease at the time of enrollment defined as T-stage ≥ Ib (Ib -&#xD;
             IV) Solitary lesion &gt; 5 cm&#xD;
&#xD;
          3. Multifocal tumors or satellite lesions present confined to the same lobe of the liver&#xD;
             as the dominant lesion but still technically resectable&#xD;
&#xD;
          4. Presence of major vascular invasion but still technically resectable&#xD;
&#xD;
          5. Suspicious or involved regional lymph nodes (N1)&#xD;
&#xD;
          6. No distant extrahepatic disease (M0)&#xD;
&#xD;
          7. High-quality cross-sectional imaging (CT or MRI) performed within 4 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          8. Adults &gt;18 years of age&#xD;
&#xD;
          9. Able to give informed consent&#xD;
&#xD;
         10. Able to adhere to study visit schedule and other protocol requirements&#xD;
&#xD;
         11. ECOG performance status of 0-1&#xD;
&#xD;
         12. Absolute neutrophil count ≥ 1500/mm3 13Platelet count ≥ 100,000/mm3&#xD;
&#xD;
        14.Albumin ≥3 g/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5x upper limit of normal&#xD;
&#xD;
          -  Serum total bilirubin &gt; 1.5x upper limit of normal&#xD;
&#xD;
          -  Presence of active infection&#xD;
&#xD;
          -  Pregnant and/or breastfeeding&#xD;
&#xD;
          -  Active other primary malignancy&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medication conditions which could compromise&#xD;
             participation in study such as unstable angina, MI within 6 months, unstable&#xD;
             symptomatic arrhythmia, symptomatic CHF, serious active or uncontrolled infection&#xD;
             after inadequate biliary drainage if tumor obstructing bile duct.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JoonOh Park, Doctor</last_name>
    <phone>82-2-3410-3459</phone>
    <email>joonoh.park@samsung.com</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Oh Park</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

